Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMTYXQF)

Drug Name	NVP-AUY922 DMTYXQF
Synonyms	Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide
Therapeutic Class	Anticancer Agents
Drug Type	Small molecular drug
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 2	[1]
Multiple myeloma	DISEWP9B	2A83	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027019)
2	ClinicalTrials.gov (NCT01854034) Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR. U.S. National Institutes of Health.